The discovery of the role of nitric oxide (NO) in the nervous system has radically altered our thinking about synaptic transmission. Although there is considerable evidence that NO functions as a neurotransmitter, it is an unusual transmitter, in that it is a labile free-radical gas that is not stored in synaptic vesicles. NO is synthesized by NO synthase (NOS) from L-arginine, and simply diffuses from nerve terminals, as opposed to the exocytosis by which conventional neurotransmitters are released. NO does not undergo reversible interactions with receptors, as do the conventional neurotransmitters, but forms covalent linkages with several potential targets, which include enzymes such as guanylyl cyclase (GC) and other protein or nonprotein molecules. The action of conventional neurotransmitters is terminated by presynaptic reuptake or enzymatic degradation, whereas the action of NO is presumably terminated by diffusion away from its targets, as well by forming covalent linkages to the superoxide anion or scavenger proteins.
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NO as a Biological Messenger
It was long believed that the biosynthesis of nitrogen oxides was an exclusive function of microorganisms, which are well known for their oxidative (nitrification) or reductive (denitrification) pathways. However, as early as 1916, it was noted that mammals secrete more nitrate in their urine than was present in their diets. Despite these initial observations, it was not until the early 1980s that nitrogen oxides were established as normal byproducts of mammalian metabolism (Green et al., 1981a,b) . Metabolites of NO increase dramatically during infection in humans as well as laboratory animals. The cytostatic and respiration-inhibiting effects of activated macrophages are dependent upon L-arginine, whose guanidino nitrogen is necessary to generate oxides of nitrogen. Analogs of L-arginine substituted on one or both of the guanidino nitrogens block macrophage cytotoxicity in a stereospecific manner, and the production of nitrite and nitrate by activated macrophages is blocked by these same analogs. Nitrites and nitrates cannot replicate the cytotoxicity of activated macrophages by themselves. However, NO closely mimics macrophage mediated cytotoxicity, while scavengers of NO block its cytotoxic effect. Thus, it has been inferred that NO is the cytotoxic agent of activated macrophages (Hibbs et al., 1987; Stuehr et al., 1989) . Attempts to elucidate the vasodilatory effects of nitroglycerin and other organic nitrates (Arnold et al., 1977; Ignarro et al., 198 l) , and the role of endothelial cells in ACh-mediated relaxation of vascular muscle (Furchgott and Zawadzki, 1980) led to the discovery that NO is the primary endogenous vasodilator released from vascular endothelium (Ignarro et al., 1987; Palmer et al., 1987) . Besides playing a role as a cytotoxic molecule of activated macrophages and relaxer of smooth muscle, NO also functions in the nervous system. For instance, cultured cerebellar granule cells release NO after exposure to glutamate analogs (Garthwaite et al., 1988) . Additionally, NO appears to be a neuromodulator or neurotransmitter because NOS inhibitors, such as nitroarginine and methylarginine, block stimulation of cGMP synthesis in brain slices by glutamate acting at NMDA receptors (Bredt and Snyder, 1989; Garthwaite et al., 1989) and block nonadrenergic noncholinergic (NANC) relaxation of intestinal smooth muscle (Bult et al., 1990; Boeckxstaens et al., 199 1; Desai et al., 199 1; Tottrup et al., 199 1) . NO Biosynthesis NO is formed directly from the guanidino nitrogen of L-arginine by NOS through a process that consumes five electrons and results in the formation ofL-citrulline (Fig. 1) . NOS is an unusual oxidative enzyme in that most other enzymes consume one or two electrons for similar functions. Attempts at the purification of NOS were initially unsuccessful, due to the rapid loss of enzymatic activity upon purification. The loss of NOS activity was eventually accounted for by separation from its necessary cofactor, calmodulin . Once it was recognized that NOS is a calmodulin-dependent enzyme, NOS could be purified to homogeneity from cerebellum . Soon thereafter, purified NOS could be isolated from a variety of other brain tissues in a variety of species (Mayer et al., 1990; Schmidt et al., 199 l) , as well as from macrophages (Hevel et al., 199 1; Stuehr et al., 1991a; Yui et al., 199 1; Evans et al., 1992) and endothelial tissue (Pollock et al., 1991) .
NOS structure and function have been clarified by the molecular cloning of the cDNA for brain (Bredt et al., 1991b; Nakane et al., 1993; Ogura et al., 1993) endothelial (Janssens Figure 1 . Biosynthesis of NO. L-Arginine is converted to NO in at least two successive steps of which a two-electron oxidation of L-arginine to N-w-hydroxy-L-arginine is the first. This hydroxylation resembles the cytochrome P450 type of monooxygenation, utilizing one equivalent each of NADPH and 0, (Marletta, 1993) . In the second step, N-w-hydroxy-L-arginine is converted to NO and citrulline. The mechanism of this conversion is less well understood, but it utilizes 0.5 equivalents of NADPH and requires 0,. Both steps require C&+ and calmodulin as activators and are accelerated by tetrahydrobiopterin, and blocked by CO (Stuehr et al., 1991b; White and Marletta, 1992) . Lamas et al., 1992; Sessa et al., 1992) macrophage NOS also uses tetrahydrobiopterin as an electron transferring Lyons et al., 1992; Xie et al., 1992) , cofactor (Kwon et al., 1989; Tayeh and Marletta, 1989 ; Mayer and non-macrophage-inducible Geller et et al., 199 1) . The exact role of tetrahydrobiopterin is not clear, al., 1993) NOS (Fig. 2) . Alternative splicing of the mRNA for but it may facilitate L-arginine binding through the stabilization neuronal NOS was revealed by the cloning of mouse neuronal of the enzyme (Giovanelli et al., 1991; Hevel and Marletta, NOS. In mouse cerebellum 10% of the NOS mRNA has a 4 15 1992; Marletta, 1993) . Recently, NOS was found to contain nucleotide deletion corresponding to nucleotides 15 1 O-l 824 heme, which reacts with CO to form a species absorbing at 445 (Ogura et al., 1993) . Cloning of human neuronal NOS reveals nm, indicating that NOS is a cytochrome P-450 enzyme (Klatt a greater abundance of neuronal NOS mRNA in skeletal muscle McMillan et al., 1992; Stuehr and Ikeda-Saito, 1992 ; than in brain, while rat skeletal muscle is almost devoid of White and Marletta, 1992) . CO inhibits purified NOS, which is neuronal NOS mRNA (Bredt et al., 199 lb; Nakane et al., 1993) .
consistent with the participation of a cytochrome P450-type The human neuronal NOS is located on chromosome 12 (Nakheme in the reaction. Moreover, NO itself appears to interact ane et al., 1993). Human endothelial NOS was mapped to chrowith the enzyme's heme and inhibit its own formation, thus mosome 7, the same chromosome that contains cytochrome exerting feedback inhibition (Assreuy et al., 1993; Rengasamy P450 reductase (Marsden et al., 1993) . The 5' promoter region and Johns, 1993). The mechanism of electron transfer is likely of the human endothelial genes contains AP-1, AP-2, NF-1 to be similar to that of the cytochrome P-450 enzymes, in that heavy metal, acute phase response shear stress, and sterol reg-NADPH reduces FAD, which subsequently reduces FMN, which ulatory elements. The human inducible NOS genes map to chroin turn transfers electrons to the ferric heme, promoting the mosome 17 (Xu et al., 1993) .
interaction with molecular oxygen. The molecular cloning data reveal the positions of recognition sites for NADPH, as well as for flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) (Bredt et al., 1991b) , which bind NOS stoichiometrically (Hevel et al., 199 1; Mayer et al., 1991; Schmidt et al., 1992b; Klatt et al., 1993) . Cytochrome P-450 reductase (CPR) is the only other mammalian enzyme known to contain recognition sites for NADPH, as well as for both FMN and FAD (Fig. 2) . The hepatic drug-scavenging cytochrome P-450 system utilizes CPR as its electron donor. CPR is 60% homologous at the amino acid level to the carboxyl-terminal half of NOS. This homology with CPR is shared by all NOS isoforms cloned and reflects the oxidative nature of NO biosynthesis. Early in evolution, NO formation presumably proceeded through donation of electrons by CPR, and at some later stage a fusion between CPR and the N-terminal half of NOS occurred. Indeed, when the C-terminal and N-terminal halves of NOS are expressed separately, and mixed, NOS catalytic activity is obtained (D. S. Bredt and S. H. Snyder, unpublished observations).
Some NOS enzymes are constitutive in the sense that their activation does not require new enzyme protein synthesis. For instance, the neuronal form of NOS, which is activated by glutamate neurotransmission acting on NMDA receptors, is clearly constitutive. Here, in a matter of seconds, the glutamate-induced increase in intracellular Ca2+ levels activates NOS via calmodulin. The endothelial form of NOS is also constitutive, being activated by increases in intracellular Ca2+ levels. Agonists such as ACh or bradykinin acting at muscarinic or bradykinin receptors, respectively, on endothelial cells, activate the phosphoinositide cycle to generate Ca2+, which then stimulates NOS by binding calmodulin. Constitutive NOS enzymes account for the role of NO in mediating rapid events, such as neurotransmission and blood vessel dilatation.
Neuronal and endothelial forms of NOS are also inducible in the sense that in the response to certain stimuli, new enzyme protein synthesis occurs. In PC-12 cells, neuronal NOS is induced after 8 d of exposure to NGF (Hirsch et al., 1993 Bredt et al., 1991b , b, Janssens et al., 1992 Lamas et al., 1992; Sessa et al., 1992; c, Lowenstein et al., 1992; Lyons et al., 1992; Xie et al., 1992; d, Charles et al., 1993; Geller et al., 1993; e, Porter and Rasper, 1985. ronal NOS mRNA in dorsal root ganglia (Verge et al., 1992) and the appearance of NOS-immunoreactive neurons (Wu et al., 1993) , which stain for NADPH-diaphorase (Solodkin et al., 1992; Vizzard et al., 1993; Wu, 1993) . Neuronal NOS is also differentially regulated in the rat and mouse developing nervous system. Though absent from dividing cells, NOS is coexpressed with the earliest markers of neuronal differentiation. Neuronal NOS activity peaks at gestational day 16, is nearly absent at birth and reappears at postnatal day 10 (Bredt and Snyder, unpublished observations). NO may regulate process outgrowth and remodeling during neuronal development that occurs at least, in part, through modulation of protein fatty acylation in growth cones (Douglas et al., 1993) . Thus, NO may be important in activity-dependent remodeling of axon terminals during development, Endothelial cells also express an increased level of endothelial NOS following middle cerebral artery occlusion (Z. G. Zhang et al., 1993) . Normally macrophages do not contain detectable levels of NOS protein. Both in vivo and in vitro stimulation with a variety of cytokines, such as y-interferon and lipopolysaccharide (LPS), elicit new NOS protein synthesis over 2-4 hr. The inducible NOS of macrophages produces large quantities of NO, which mediate destruction of microorganisms and tumors and may also lead to pathologic tissue damage. Inducible NOS of macrophages is not stimulated by Caz+, but surprisingly, inducible NOS enzymes do possess calmodulin recognition sites (Fig. 2) . Calmodulin is very tightly bound to inducible macrophage NOS , with the binding unaffected by Caz+, whereas calmodulin cannot bind to neuronal NOS unless Ca2+ is present. Thus, calmodulin may be considered a protein subunit of inducible macrophage NOS, which accounts for its resistance to Cal+ activation (Nathan, 1992) . Since the demonstration that macrophages contain an inducible form of NOS, inducible NOS activity has been found also following endotoxin treatment in a diversity of tissues lacking macrophages (Nathan, 1992) . Brain astrocytes and microglia possess an inducible NOS, which is induced by a variety of cytokines . Induction of inducible NOS in astrocytes and microglia may account for the tissue damage associated with a variety of neurologic disorders . Astrocytes and microglia also possess a Ca*+-dependent NOS which is constitutively expressed . The inducible NOS of human hepatocytes (Geller et al., 1993) and chrondocytes has recently been cloned and might represent the prototype for a non-macrophage-inducible NOS. The ubiquitous distribution of this type of inducible NOS may reflect a primitive sort of immune response to invading microbial pathogens.
Consensus sequences for phosphorylation by CAMP-dependent protein kinase are evident in neuronal, endothelial, and Nakane et al., 199 1; . Phosphorylation by all these enzymes decreases NOS catalytic activity (J. L. Dinerman, J. P. Steiner, T. M. Dawson, and S. H. Snyder, unpublished observations) . NOS is also a calcineurin substrate, with calcineurin dephosphorylating NOS and increasing its catalytic activity (T. M. Dawson et al., 1993) . Multiple levels of constitutive neuronal NOS regulation are thus possible by phosphorylation. Ca2+/calmodulin can directly activate NOS and also increase its catalytic activity by activation of calcineurin to dephosphorylate it. But, Ca2+/calmodulin can activate Ca2+/calmodulin-dependent protein kinase to enhance phosphorylation of NOS and hence decrease its catalytic activity. In conjunction with lipids Ca2+ can activate protein kinase C, whose phosphorylation of NOS would decrease its activity. Activation of guanylyl cyclase by NO to form cGMP could act as a negative feedback mechanism, in that increased levels of cGMP would activate a cGMP-dependent protein kinase whose phosphorylation of NOS would decrease its activity.
One would expect regulation of inducible NOS to occur at the level of gene transcription and enzyme protein synthesis. Characterization of the promotor region of the gene for macrophage-inducible NOS (macNOS) reveals a complex pattern of regulation Xie et al., 1993) . LPS and y-interferon responsive elements occur in two distinct regulatory sites with LPS directly stimulating macNOS expression while y-interferon acts only in the presence of LPS. Upstream from the transcription start site there appear to be two distinct regulatory regions upstream of the TATA box. Region 1, which lies about SO-200 base pairs upstream of the start site, contains LPS-related response elements, such as the binding site for NF-IL6 and the binding site for NFkappaB (NFKB), indicating that this region regulates the LPS-induced expression of macNOS. Region 2, which lies about 900-1000 base pairs upstream of the start site, contains motifs for y-interferon-related transcription factors. Activation of region 2 provides a further IO-fold increase above the 75fold increase in NOS expression provided by activation of region 1, but does not in itself directly regulate NOS expression. This complex organization of the macNOS promotor may explain some important aspects of inflammation. For instance, in sepsis, gram negative bacteria release LPS, which circulates throughout the body and sets off an inflammatory response. y-Interferon, in contrast, is released locally by infiltrating lymphocytes and serves to augment the inflammatory response, by priming the macrophages for a maximal LPS induction of NOS. Thus, maximal production of NO is restricted to those macrophages that are in close proximity to the site of cellular insult, thereby minimizing damage to adjacent healthy tissue.
Neuronal NOS has a molecular weight of 160 kDa, whereas endothelial and macrophage NOS are about 130 kDa. All isoforms occur as dimers. Neuronal and macrophage NOS have been characterized as soluble proteins, but subcellular fractionation studies reveal that a significant amount of neuronal NOS is present in the particulate fraction (Hiki et al., 1993) . The properties of neuronal NOS that facilitate incorporation in the particulate fraction are presently unclear, but could involve protein modifications or interactions with novel binding proteins. In contrast, endothelial NOS is predominantly present in the particulate fraction. Molecular cloning of endothelial NOS reveals no obvious transmembrane spanning regions (Janssens et al., 1992b; Lamas et al., 1992; Sessa et al., 1992) , but there is a consensus motif for N-terminal myristoylation, whose mutational deletion renders endothelial NOS soluble ). In addition, )H-myristate is directly incorporated into endothelial NOS, and insertion of the myristoyl group into the plasma membrane presumably accounts for the enzyme's location in the particulate fraction .
Neuronal Function and NO
Immunohistochemical staining with an antibody raised against the purified neuronal NOS antigen showed that brain neuronal NOS occurs only in neurons. NOS neurons comprise only about l-2% of all the cells in many areas, such as the cerebral cortex, the hippocampal formation, and corpus striatum. NOS neurons are not displayed in an obvious pattern and exhibit morphologic properties of medium to large aspiny neurons that are scattered throughout the same regions. In the hippocampus, none of the pyramidal cells contain neuronal NOS (Bredt et al., 1991a; Schmidt et al., 1992a; Dinerman et al., 1994) but there are numerous NOS intemeurons with extensive processes throughout the CA1 region of the hippocampus. Granule cells of the dentate gyrus of the hippocampus, in contrast, have abundant neuronal NOS. In the hypothalamus, NOS neurons are evident within the paraventricular magnocellular neurons as well as the supraoptic neurons that project to the posterior pituitary, which contains's dense plexus of NOS fibers. The midbrain contains a dense plexus of NOS neurons, fibers, and terminals within the superficial layers of the superior and inferior colliculi. NOS neurons are also abundant within the lateral dorsal tegmental and pedunculopontine tegmental nuclei, which innervate several thalamic nuclei (Bredt et al., 1990, 199 1 a) .
In the cerebellum, NOS is present in granule cells and their parallel fiber axon terminals as well as basket cells, but not in Purkinje cells. Glutamate raises cGMP levels in the cerebellum through stimulation of NMDA receptors that are present on granule cell parallel fiber axon terminals and basket cells, which conceivably triggers the formation of NO that diffuses to the adjacent Purkinje cells to activate guanylyl cyclase. cGMP is selectively concentrated in Purkinje cells that receive input from terminals of granule and basket cells. While NO clearly activates guanylyl cyclase in the cerebellum as well as other brain regions, this association may not be universal throughout the brain. If NO exclusively activated guanylate cyclase, then localizations of guanylyl cyclase and NOS should be closely similar. Since they differ markedly, NO probably influences other targets; alternatively, guanylyl cyclase may be the target for other transmitters besides NO.
There does not appear to be a specific pattern of neurotransmitter colocalization for NOS. In the cerebellum NOS occurs in glutaminergic granule cells as well as GABAergic basket cells. In the cerebral cortex, NOS neurons contain GABA, somatostatin, and neuropeptide Y (Vincent et al., 1983 ; T. M. Dawson et al., 1991) . In the corpus striatum all NOS neurons stain for somatostatin and neuropeptide Y, while in the pedunculopontine tegmental nucleus of the brainstem, NOS neurons lack somatostatin and neuropeptide Y, but stain for ChAT (T. M. Dawson et al., 1991 (Thomas and Pearse, 196 1, 1964) resulting in a blue formazan precipitant. Transfection of cultured human kidney-293 cells, lacking NOS or diaphorase, with neuronal NOS cDNA produced cells that stain for both NADPH-diaphorase and NOS. NOS and NADPH-diaphorase staining in these cells occur in exactly the same proportion as neurons in the brain, establishing that NOS catalytic activity accounts for diaphorase staining (T. M. Dawson et al., 1991) . In brain homogenates, most of the diaphorase activity is unrelated to NOS (Hope et al., 1991) . However, in paraformaldehyde-fixed tissue, NADPH-diaphorase staining is coincident with NOS immunoreactivity in neurons (T. M. Dawson et al., 199 1) . The paraformaldehyde fixation presumably inactivates virtually all NADPH-dependent oxidative enzymes except NOS, enabling the NADPH-diaphorase stain to label NOS neurons selectively. NADPH-diaphorase/NOS-containing cells are unusual in that they are notably resistant to destruction in Huntington's and Alzheimer's disease, vascular stroke, and NMDA neurotoxicity (Ferrante et al., 1985; Koh et al., 1986; Koh and Choi, 1988; Uemura et al., 1990; Hyman et al., 1992) .
What are the normal functions of NOS neurons? NO appears to influence neurotransmitter release. In several model systems, NOS inhibitors, such as nitroarginine, block the release of neurotransmitters (Dickie et al., 1992; Hanbauer et al., 1992; Lonart et al., 1992; Zhu and Luo, 1992) . Release of ACh in response to depolarization, by increasing the extracellular potassium (K+ ) concentration, is markedly enhanced after 8 d of NGF application (Hirsch et al., 1993) to cultured PC-12 cells. K+ depolarization in cultured PC-12 cells after NGF treatment also elicited a marked enhancement of cGMP levels that was coincident with the marked enhancement of ACh release (Sandberg et al., 1989a,b) . NOS accounts for the marked enhancement in ACh release and the accompanying increase in cGMP levels. Release of both ACh and dopamine from NGF-treated PC-12 cells is blocked by NOS inhibitors and reversed by excess L-arginine (Hirsch et al., 1993) . Furthermore, in brain synaptosomes the release of neurotransmitter invoked by stimulation of NMDA receptors is blocked by nitroarginine. The exact mechanism whereby NO enhances neurotransmitter release is unclear, but may involve phosphorylation of synaptic vesicle proteins through activation of guanylyl cyclase.
NO has been implicated in hippocampal long-term potentiation (LTP), and perhaps NO's enhancement of neurotransmitter release facilitates the neurotransmission that accounts for LTP. For instance, injection of nitroarginine into the postsynaptic CA1 pyramidal cells of the hippocampus inhibits presynaptic LTP (Schuman and Madison, 199 l) , suggesting that NO might act as a retrograde messenger for LTP O'Dell et al., 1991; Haley et al., 1992) . Despite the electrophysiologic evidence for NO in hippocampal LTP, neuronal NOS was not found within the postsynaptic CA1 pyramidal cells . NADPH-diaphorase staining has yielded inconsistent staining of CA 1 pyramidal neurons (Bredt et al., 199 1 a; Schmidt et al., 1992a; Vincent and Kimura, 1992) . Very low levels of CA1 pyramidal cell staining were observed with a neuronal NOS antibody under special fixation procedures using much higher concentrations of the NOS antibody than are required for staining of other NOS neurons (Schweizer et al., 1993) . Recently, endothelial NOS was shown to be highly concentrated in CA 1 pyramidal cells and dendrites, and under glutaraldehyde fixation CA 1 pyramidal cells stain for NADPH diaphorase; thus, endothelial NOS may generate the NO that has been postulated as a retrograde messenger in LTP (Dinerman et al., 1994) .
A specific neurotransmitter function of NO has been demonstrated in the autonomic PNS. Throughout the gastrointestinal tract, NOS neurons are present in the myenteric plexus ; T. M. Dawson et al., 1991) . Depolarization of myenteric plexus neurons relaxes smooth muscle associated with peristalsis. Blockade of this process by NOS inhibitors indicates that NO is the transmitter for NANC relaxation of the gut (Snipes et al., 1987; Bult et al., 1990; Desai et al., 1991; Tottrup et al., 199 1) .
NOS neurons are also prominent in penile tissue, specifically in the pelvic plexus and its axonal processes that form the cavernous nerve as well as the nerve plexus in the adventitia of the deep cavemosal arteries and the sinusoids in the periphery of the corpora cavemosa (Burnett et al., 1992) . Intravenous injection of NOS inhibitors blocks the penile erection that is elicited upon electric stimulation of the cavernous nerve (Burnett et al., 1992) . Nerve-stimulated relaxation of isolated cavemosa strips is also blocked by NOS inhibitors (Rajfer et al., 1992) . These findings establish NO as the NANC transmitter mediating penile erection.
In the cerebral cortical and retinal blood vessels, besides localizations in the endothelium, NOS occurs in autonomic nerves in the outer, adventitial layers. These neurons derive from cells primarily in the sphenopalatine ganglia at the base of the skull (Nozaki et al., 1993; Yamamoto et al., 1993) , which also contain the neuropeptide, vasoactive intestinal polypeptide (Nozaki et al., 1993) . NO mediates vasodilation in the cerebral arteries through an NANC mechanism (Faraci, 1992; Prado et al., 1992; Toda et al., 1993) . Cerebral blood flow is regulated by NO released both from endothelial cells as well as from the autonomic nerves within the adventitia. NO may also regulate cerebral blood flow through activity-dependent activation of NOS neurons influencing the small cerebra1 arterioles (Iadecola, 1993) .
NOS occurs in discrete ganglion cells and fibers in the adrenal medulla ; T. M. Dawson et al., 1991) , where it may regulate blood flow through a NANC mechanism (Breslow et al., 1992) . NOS is also prominent within the posterior pituitary gland in fibers and terminals, where the function of NO has not yet been established.
In the spinal cord NOS is localized in the substantia gelatinosa and the intermediolateral cell column and neurons around the central canal. In these areas, NOS may influence functions of the sympathetic and parasympathetic autonomic nervous system (Meller and Gebhart, 1993) . Indeed, NO has been implicated as a mediator of pain, since inhibitors of NOS attenuate thermal hyperalgesia (Meller and Gebhart, 1993) . NO may also be involved in morphine tolerance, since coadministration of nitroarginine with morphine markedly retards the development of tolerance (Kolesnikov et al., 1993) . Nitroarginine does not prevent tolerance to analgesia mediated by the K-SekCtiVe opiate agonists indicating that NO has a selective action in p-opiate tolerance.
Homologous genetic recombination techniques have recently been used to disrupt the murine gene encoding neuronal NOS and produce homozygous neuronal NOS "knockout" mice (Huang et al., 1993) . The animals are normal in most respects despite their lack of NOS catalytic activity in the brain and loss of NOS immunostaining in central and peripheral neurons. Gross and microscopic examination fails to reveal morphologic ab- Dawson and Snyder * Gases as Biologic Messengers normalities in the brain and most peripheral tissue. However, the stomachs of null mice are grossly distended, and histologic examination shows hypertrophy of the circular muscle layer, especially in the pyloric region, consistent with chronic muscle contraction. The pathology resembles hypertrophic pyloric stenosis, in which the lack of NO may play a role since a recent study shows an absence of NADPH-diaphorase staining in the myenteric neurons of human male infants with pyloric stenosis (Vanderwinden et al., 1992) . NADPH-diaphorase staining is normal outside the pyloric region in these patients, so that a generalized deficiency in neuronal NOS is probably not the cause of this disorder.
Although NO increases cGMP levels, the exact function of cGMP in the brain remains obscure, though it is known to activate cGMP-dependent serine/threonine protein kinase, cGMP-dependent cation channels (Light et al., 1989; Fesenko et al., 199 1) , and cGMP-dependent phosphodiesterases (Beavo and Reifsnyder, 1990) . NO activation of the cGMP pathway in rat dorsal root ganglion cells desensitizes bradykinin inward cation currents (McGehee et al., 1992) indicating that NO may be involved in desensitization pathways. CAMP signaling may also be regulated by cGMP-modulated phosphodiesterases that hydrolyze CAMP. An interaction between CAMP and cGMP mediates NO activation of immediate early gene expression in PC-12 cells (Peunova and Enikolopov, 1993) .
NO binds iron in the heme of guanylyl cyclase, altering the enzyme's conformation to activate it. In addition, NO can bind to non-heme iron in numerous enzymes such as NADH: succinate oxidoreductase, NADH-ubiquinone oxidoreductase, and cis-aconitase, all iron-sulfur-containing enzymes (Hibbs et al., 1990; Nathan, 1992) . NO can also bind to the iron in ferritin, an iron storage protein, liberating the iron that could cause lipid peroxidation (Reif and Simmons, 1990) . NO may inhibit DNA synthesis through binding the non-heme iron of ribonucleotide reductase (Lepoivre et al., 1990; Kwon et al., 199 1) . The ability of NO to bind iron could influence iron metabolism. Iron metabolism is regulated posttranscriptionally by specific mRNAprotein interactions. Iron-responsive elements (IRE) occur in mRNA encoding the erythroid form of 5aminolevulinate synthase, ferritin, and the transferrin receptor (Klausner and Rouault, 1993; Munro, 1993) . A soluble protein, IRE-binding protein (IRE-BP), binds to IRE, regulating expression of proteins whose mRNA contain IRE motifs. NO augments the IRE-binding activity of IRE-BP, influencing iron metabolism at the posttranscriptional level (Drapier et al., 1993; Weiss et al., 1993) . NO produced by NMDA receptor activation of cerebellar slices also augments the mRNA binding activity of IRE-BP (S. E. Jaffrey, N. Cohen, T. A. Rouault, R. D. Klausner, and S. H. Snyder, unpublished observations).
NO influences the activity of cyclooxygenase, which contains heme (Salvemini et al., 1993) . Cyclooxygenase is the rate-limiting enzyme in the biosynthesis of prostaglandins, thromboxane A, and prostacyclins. NO increases prostaglandin production by activation ofcyclooxygenase (Salvemini et al., 1993) . In macrophages, the NO-mediated increase in the production of proinflammatory prostaglandins through activation of cyclooxygenase may result in an exacerbated inflammatory response. In the hypothalamus, NO may mediate norepinephrine-induced prostaglandin E, release by activating cyclooxygenase (Rettori et al., 1992) . Corticotropin-releasing hormone release from the hypothalamus (Costa et al., 1993; Karanth et al., 1993 ) stimulated by IL, or carbachol occurs through increases in prostaglandin Ez levels by virtue of NOS activation of cyclooxygenase (Karanth et al., 1993) .
NO can stimulate the S-nitrosylation of many proteins (Stamler et al., 1992a,b) . Nitrosylation of the NMDA receptor by NO inactivates it (Lipton et al., 1993) and may physiologically modulate glutamatergic transmission (Manzoni and Bockaert, 1993) . NO stimulates the apparent autoADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase (Dimmeler et al., 1992; Kots et al., 1992; Zhang and Snyder, 1992) . This reaction involves a cysteine at the active site of the enzyme, inhibiting catalytic activity and potentially depressing glycolysis. The apparent ADPribosylation may reflect a direct binding of NAD to the cysteine by S-nitrosylation (McDonald and Moss, 1993) .
NO as a neurotoxin Although NO mediates normal synaptic transmission, it may be neurotoxic under conditions of excessive formation of NO. Glutamate released in excess acting primarily through NMDA receptors mediates neurotoxicity in focal ischemia since the neurotoxicity is blocked by NMDA antagonists (Choi, 1988; Meldrum and Garthwaite, 1990) . Glutamate neurotoxicity may also contribute to neurodegeneration in Alzheimer's and Huntington's diseases. Presumably activation of NMDA receptors and the subsequent increase in intracellular CaZ+ levels initiate most forms of glutamate neurotoxicity (Meldrum and GarthWaite, 1990 ). Glutamate neurotoxicity is attributable at least, in part, to NOS activation evoked by the increased intracellular Ca2+ concentration. In primary cultures of cerebral cortical neurons, in which a short (5 min) exposure to NMDA (500 PM) normally elicits cell death 24 hr later, inhibitors of NOS, including arginine analogs, calmodulin antagonists, and flavoprotein inhibitors, and reduced hemoglobin, which scavenges NO, markedly attenuate neurotoxicity (V. L. Dawson et al., 1991 Dawson et al., , 1993a . Glutamate neurotoxicity is also diminished by culture in L-arginine-free media (V. L. Dawson et al., 199 1, 1993a) . Blockade of toxicity by NOS inhibitors is also observed in cultures of caudate-putamen and hippocampus (V. L. Dawson et al., 1993a) . Superoxide dismutase (SOD), which scavenges the superoxide anion, attenuates glutamate neurotoxicity, implicating the superoxide anion in components of this process (V. L. Dawson et al., 1993a) . NO and the superoxide anion may interact to form peroxynitrite, which is the ultimate toxic molecule (Beckmanet al., 1990; Beckman, 1991; Radi et al., 199la,b) . NO has been implicated in glutamate neurotoxicity in a variety of tissues including striatal slices (Kollegger et al., 1993) , hippocampal slices (Izumi et al., 1992; Moncada et al., 1992; Wallis et al., 1992) , and culture conditions (Corasaniti et al., 1992; Lustig et al., 1992; Tamura et al., 1992; Cazevieille et al., 1993) . Prolonged application of NOS inhibitors after the initial exposure to excitatory amino acids leads to enhanced neuroprotection (Reif, 1993; Vige et al., 1993) . Despite the above-cited evidence for a role of NO in glutamate neurotoxicity other investigators failed to confirm that NO is a necessary link in this phenomenon (Demerle-Pallardy et al., 199 1; Pauwels and Leysen, 1992; Regan et al., 1993) or even provided evidence that NO may protect neurons form glutamate toxicity (Lei et al., 1992) . These discrepancies have been resolved by the finding that NO may possess either neurodestructive and neuroprotective properties, depending upon its oxidation-reduction status, with NO being neurodestructive and NO+ being neuroprotective (Lipton et al., 1993) .
If NO is responsible for neuronal damage in vascular stroke, inhibitors of NOS should be neuroprotective. Low doses of nitroarginine reduce infarct volume following middle cerebral artery occlusion in rats (Buisson et al., 1992; Nagafuji et al., 1992; Trifiletti, 1992; Buisson et al., 1993) cats (Nishikawa et al., 1993) and mice (Nowicki et al., 199 1) . High doses of NOS inhibitors exacerbate the damage following occlusion of the middle cerebral artery, presumably by decreasing cerebral blood flow Yamamoto et al., 1992) . NOS neurons are peculiar, in that they are resistant to NMDA toxicity and exquisitely sensitive to quisqualate and kainate neurotoxicity (Koh and Choi, 1988) . Low-dose quisqualate pretreatment of cortical cultures selectively kills NOS neurons, while non-NOS neurons remain viable (V. L. Dawson et al., 1993a) . Quisqualate-pretreated cortical cultures are resistant to NMDA toxicity (V. L. Dawson et al., 1993a) . Thus, NOS neurons release NO to kill non-NOS neurons. The peculiar resistance of NOS neurons to NMDA toxicity is puzzling (V. L. Dawson et al., 1993a) . Perhaps the diaphorase activity of NOS protects the cell against NO, as induction of a related diaphorase enzyme renders a non-NQS neuronal cell line resistant to glutamate toxicity (Murphy et al., 199 1) . NOS neurons within the striatum are enriched in manganese SOD (Inagaki et al., 199 l) , and SOD in these neurons may prevent the local formation of toxic peroxynitrite rendering NOS neurons resistant to the toxic actions of NO. Another possibility involves a potential intracellular translocation of neuronal NOS that has been demonstrated for endothelial NOS . Phosphorylation of endothelial NOS translocates it from membrane to cytosol. Since phosphorylated NOS is catalytically inactive, NO will not be generated within the cytoplasm. Instead, catalytically active, nonphosphorylated NOS is restricted to the plasma membrane, where it presumably generates NO that is released into the extracellular space. Neuronal NOS is present in both the particulate and soluble fractions (Hiki et al., 1993) . Thus, it is conceivable that within neurons the active form of NOS occurs at the plasma membrane, where it releases NO to the outside, and no NO would be produced in the interior of NOS cells, rendering them resistant to NO damage.
Other types of neurotoxicity can be mediated by NO. The pathogenesis of AIDS dementia has remained elusive, as HIV-1 infection has been detected in macrophages and microglia but not in neurons (Koenig et al., 1986; Giulian et al., 1990; Watkins et al., 1990) . Neuronal cell death might involve the HIV-1 coat protein, gp120, which is shed by the virus, since picomolar concentrations of gpl20 kill neurons in primary cortical cell cultures (Brenneman et al., 1988; Dreyer et al., 1990) . Neuronal cell death elicited by gp 120 is absolutely dependent upon the presence of glutamate acting through NMDA receptors (Lipton et al., 1991; V. L. Dawson et al., 1993b) . This neurotoxicity is mediated, at least in part, by NO since inhibitors of NOS and culture in arginine-free medium block gp 120 neurotoxicity (V. L. Dawson et al., 1993b) . How gp120 elicits the formation of NO is unclear, but gp 120 neurotoxicity requires the presence of macrophages and/or astrocytes (Lipton, 1992) , and these cells produce cytokines and arachidonic acid metabolites that can potentiate NMDA receptor currents. Conceivably, gp 120 elicits release of arachidonic acid metabolites and/or cytokines from macrophages and glia, which synergize with glutamate to activate NMDA receptors that in turn enhance the formation of NO, which is toxic to neurons (Fig. 3) .
NOS can be inhibited indirectly, which thus provides alternative strategies for protection against NO-mediated cell death. Dawson et al. (1993b) .
Gangliosides are neuroprotective in spinal cord injury in human patients as well as in animal models of other types of neuronal damage (Manev et al., 1990; Geisler et al., 1992; Mahadik, 1992; Skaper and Leon, 1992) . Gangliosides prevent glutamate neurotoxicity in neuronal cultures because they inhibit NOS activity (T. M. Dawson et al., 1994) . The protective potency of gangliosides closely parallels their affinities for calmodulin and their potency for inhibiting NOS (T. M. Dawson et al., 1994) . Phosphorylation of NOS and the attendant reduction of its catalytic activity provides another potential approach to protection. The immunosuppressants FK506 and cyclosporin-A bind to small soluble receptor proteins designated FKSO6-binding proteins (FKBP) and cyclophilins, respectively. The drug receptor complex in turn binds to the Ca2+-activated phosphatase calcineurin and inhibits its activity (Fruman et al., 1992; Liu et al., 199 1, 1992; Swanson et al., 1992) . The inhibition of calcineurin accounts for FK506 and cyclosporin-A's immunosuppressant actions on T cells and explains their effects in the CNS as these drugs lead to an accumulation of phosphorylated substrates of calcineurin (Steiner et al., 1992) . NOS is a calcineurin substrate, and the abundance of phosphorylated catalytically inactive NOS is enhanced by FK506 and cyclosporin-A (T. M. Dawson et al., 1993) . Accordingly, since they favor the accumulation of catalytically inactive NOS, FK506 and cyclosporin-A provide protection against glutamate toxicity (Fig.  4) . The neuroprotective effects of the immunosuppressants may have clinical relevance, as cyclosporin-A reduces infarct volume following middle cerebral artery infarction in rats (Shiga et al., 1992) .
The toxic effects mediated by NO probably evolve from its interaction with the superoxide anion to form peroxynitrite (Beckman et al., 1990; Beckman, 1991; Radi et al., 1991a,b) . Recent studies provide evidence that DNA damage is the key to NO neurotoxicity (J. Zhang et al., 1994) . DNA damage by NO, as with other free radicals, occurs through nucleotide base deamination (Wink et al., 1991 Figure 4 . Regulation ofthe phosphorylation state and catalytic activity of NOS. NMDA receptor (NMDA-R) activation increases intracellular Cal+ levels, which activates NOS and calcineurin via calmodulin (CaM). NOS catalytic activity is inhibited by protein kinase (IX)-mediated phosphorylation by CAMP and cGMP-dependent protein kinases, protein kinase C and Ca*+/calmodulin-dependent protein kinase. Ca2+ entry activates calcineurin, which dephosphorylates and reactivates NOS. FK506, complexed to FKRP, binds to calcineurin and inhibits its phosphatase activity. This prevents the dephosphorylation of NOS, thus decreasing NOS catalytic activity. NO production is consequently lowered, and adjacent neurons survive. Figure is from T. M. Dawson et al. (1993). leads to DNA fragmentation, which stimulates the activity of the nuclear enzyme poly (ADP ribose) synthetase (PARS). Utilizing NAD as a substrate, PARS catalyzes the attachment of 50-l 00 ADP-ribose units per molecule of nuclear proteins such as histones and, most prominently, to PARS itself (de Murcia et al., 199 1) . NO stimulates the polyADP-ribosylation of PARS in brain homogenates by damaging DNA (J. Zhang et al., 1994) . In cortical cell cultures, glutamate neurotoxicity is blocked by a series of PARS inhibitors, whose capacity for neuroprotection increase with their potencies for PARS inhibition (J. Zhang et al., 1994) . These observations indicate the following scenario for NO neurotoxicity (Fig. 5) . DNA damage produced by NO causes a massive activation of PARS, which severely depletes the cell of NAD and ATP. For each mole of ADP-ribose transferred, 1 mol of NAD and, through the regeneration of NAD, the free energy equivalent of 4 mol of ATP are consumed. Since NO poisons the mitochondrial electron transport chain as well, PARS activation can lead to a rapid depletion in energy stores. With lesser degrees of DNA damage, PARS activation is thought to facilitate DNA repair (Gaal et al., 1987) .
Carbon monoxide as a neural messenger NO may not be the only gaseous, labile small molecule neurotransmitter, in that CO has recently turned up as another neurotransmitter candidate. CO is produced by heme oxygenase which cleaves the heme ring into CO and biliverdin, which is rapidly reduced to bilirubin. There are at least two isoforms of and ATP. This futile cycle continues during the prolonged PARS activation, depleting the cell's energy and ultimately leading to its death. From J. Zhang et al. (1994) .
heme oxygenase (HO). HO1 is inducible and is responsible for the destruction of heme in senescent red blood cells (Cruse and Maines, 1988; Sun et al., 1990) . Expression of HOI protein is induced in response to accumulation of heme, as well as by oxidative stressors. The other isoform, H02, is constitutive. HO1 is concentrated in peripheral tissues, such as the spleen and liver, whereas HO2 occurs in high densities in the brain (Sun et al., 1990; Verma et al., 1993) . HO resembles NOS in that the electrons for CO synthesis are donated by CPR. CO, like NO, binds to the iron in heme in guanylate cyclase to activate cGMP (Briine and Ullrich, 1987; GrHser et al., 1990; Furchgott and Jothianandan, 199 1; Marks et al., 1991 ). CO's affinity for heme accounts for its lethality, in that it prevents hemoglobin from delivering oxygen to the tissues. HO was generally thought to serve primarily for heme catabolism. However, it was found that in cultures of olfactory neurons, CO is responsible for maintaining endogenous cGMP levels, since potent and selective inhibitors of HO, but not NOS inhibitors, deplete cGMP levels (Verma et al., 1993) . Moreover, a variety of odorants seemed to enhance the level of cGMP via a COdependent mechanism (Vet-ma et al., 1993) . Further evidence that HO may play a role in neurotransmission is that HO displays selective localizations in the brain. For instance, high concentrations of HO2 are present in hippocampal pyramidal and granule cells. In the cerebellum, high concentrations are present in the granule and Purkinje cell layers. HO2 is also found in the piriform cortex, tenia tecta, olfactory tubercle, and islands of Callejae (Verma et al., 1993) . Highest concentrations in the brain occur in the neurons of the olfactory epithelium and in the neuronal and granule cell layers of the olfactory bulb (Verma et al., 1993) . Immunohistochemical studies of HO2 provide somewhat similar localizations (Ewing and Maines, 1992; J. L. Dinerman and S. H. Snyder, unpublished observations). Although CO has only been recently identified in the brain, it has been implicated in various physiologic functions. With HO2 being concentrated in hippocampal pyramidal cells, CO might be a candidate retrograde messenger for LTP since the HO inhibitor zinc protoporphyrin IX (ZnPP-9) blocks the induction of LTP in hippocampal slices (Stevens and Wang, 1993; Zhuo et al., 1993) . In addition, long-lasting increases in the amplitude ofevoked potentials are observed when CO is applied at the same time as a weak tetanic stimulation (Zhuo et al., 1993) . NO primarily mediates glutamate action at NMDA receptors and CO may be primarily responsible for mediating glutamate action at metabotropic receptors. Metabotropic receptor activation in the nucleus tractus solitarius ofthe brain stem regulates the conductance of a specific channel via a cGMP-dependent mechanism. ZnPP-9 and other antagonists block effects of receptor stimulation in proportion to their potencies as inhibitors of HO, while NOS inhibitors do not reduce the agonist induced increase in channel conductance (Glaum and Miller, 1993) .
The chemosensors of the carotid body may also be subject to regulation by CO. They are activated by molecular oxygen and inhibited by CO (Gonzalez et al., 1992) . The carotid body possesses high concentrations of HO2 protein, as determined immunohistochemically (J. L. Dinerman, N. R. Prabhakar, and S. H. Snyder, unpublished observations), and ZnPP-9 markedly enhances chemosensory discharges of the carotid body (Prabhakar et al., 1993 ).
Summary
In a remarkably brief period of time, NO and CO have been recognized as putative neurotransmitters. These two novel messenger molecules have greatly expanded the criteria for candidacy of a chemical for the status of neurotransmitter and our notions about how synaptic transmission takes place. The involvement of NO and CO in several important aspects of neuronal function suggests that agents affecting the synthesis, transactions, and disposition of these gases are bound to have clinical relevance. Dawson and Snyder * Gases as Biologic Messengers of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Nat1 Acad Sci USA 90:9808-98 12. Dawson TM, Hung K, Dawson VL, Steiner JP, Snyder SH (1994) Neuroprotective effects of ganghosides may involve inhibition of nitric oxide synthase. Ann Neurol, in press. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical culture. Proc Nat1 Acad Sci USA 88:6368-637 1. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH (1993a) Mechanisms of 
